BioVie Inc. Stock Price

NasdaqCM:BIVI Community·US$13.6m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

Create a narrative

BIVI Share Price Performance

US$1.77

-25.63 (-93.54%)

US$1.77

-25.63 (-93.54%)

US$1.77

Fri, 31 Oct 25

Share PriceUS$1.77

BIVI Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

7 Risks

1 Reward

View Full Analysis

BioVie Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -2.38
: 0%
: 0%
: 0%

View Full Analysis

About BIVI

Founded: 2013
Employees: 13
CEO: Cuong Viet Do
WebsiteView website: bioviepharma.com

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.